Abbott Laboratories (ABT) climbs after posting stronger-than-expected second-quarter results and raising full-year profit guidance. The healthcare giant’s earnings beat, sales growth, and improved outlook are driving a sharp revaluation as investors reassess its earnings power and recovery potential.
Abbott Laboratories (ABT) climbed 12.5% after delivering a Q2 earnings beat and lifting its full-year adjusted EPS outlook. The move was driven by stronger sales, especially in diagnostics, and signals that Abbott’s earnings power is improving faster than the market expected. For investors, the rally resets the stock’s near-term outlook and reinforces ABT as a large-cap healthcare name with renewed momentum.
Abbott Laboratories (ABT) climbs 12.48% today after the healthcare giant posted a stronger second quarter and lifted its full-year profit outlook. For a $174.90B medical devices and diagnostics company with a 0.607 beta, that is a sharp move, and it points to a fast repricing of earnings power rather than routine sector drift.
Key Takeaways
Abbott Laboratories (ABT) is up 12.48% after reporting Q2 2026 adjusted EPS of $1.31 on $12.593B in sales.
The main catalyst is a raised 2026 adjusted EPS outlook to $5.45-$5.60 from $5.38-$5.58, alongside 6.5%-7.5% comparable sales growth guidance.
The quarter beat Wall Street expectations, with adjusted EPS above the $1.28 consensus and revenue up 13.0% year over year.
Diagnostics was a major support point, with $3.092B in sales and 42.3% reported growth, helped by the Exact Sciences acquisition completed on March 23, 2026.
For investors, the move matters because ABT still trades well below its 52-week high of $134.3838, even after today's rally.
Why Abbott Laboratories Stock Is Climbing Today
The clearest reason for Abbott Laboratories (ABT) stock strength today is its Q2 2026 earnings report. Abbott posted adjusted diluted EPS of $1.31, up from $1.26 a year earlier and above the $1.28 Wall Street estimate. Revenue reached $12.593B, up 13.0% on a reported basis.
More important, Abbott raised full-year 2026 adjusted EPS guidance to $5.45-$5.60 from $5.38-$5.58. That is the kind of change that gets institutions moving. A company this large does not jump more than 12% on vague optimism. It jumps when the market decides prior profit assumptions were too low.
There were other supportive items in recent days, including a Baird initiation with an Outperform rating on July 13 and a declared $0.63 quarterly dividend. Still, those were side notes. The earnings beat and guidance raise are the real engine behind today's move.
Abbott Q2 2026 Results Show Broad Business Strength
The quarter was not perfect, but it was broad enough to support the rally. Diagnostics sales were $3.092B, up 42.3% reported and 2.9% on a comparable basis. Established Pharmaceuticals added $1.499B, up 8.4% reported and 8.7% comparable. Nutrition was softer at $2.144B, down 3.1% reported and 3.6% comparable.
That mix matters. Abbott is not a one-product story. It sells across diagnostics, nutrition, devices, and established pharmaceuticals, which gives the business more balance than many healthcare peers. When one unit cools off, another can carry the load. In this quarter, diagnostics did the heavy lifting.
The Exact Sciences acquisition, completed on March 23, 2026, also helped reshape the quarter. Abbott said 2026 reporting now includes Cancer Diagnostics. That expands its reach in a higher-growth testing market and gives investors another reason to revalue the diagnostics franchise.
Just as important, Abbott returned $2.1B to shareholders in Q2 through dividends and buybacks. For a company that also yields 2.65%, that combination of growth and capital return tends to attract both defensive and total-return investors.
Abbott Laboratories Valuation and Market Position After the Rally
Even after today's surge, Abbott's valuation does not look extreme for a diversified healthcare leader. The stock trades at a P/E of 24.9188. That is not cheap in absolute terms, but it is easier to defend when earnings are rising and guidance is moving higher.
There is also a useful market context here. ABT closed at $100.41 and still sits well below its 52-week high of $134.3838. The stock has been under pressure over the past year, so today's jump looks less like euphoria and more like a reset after a depressed stretch. Sometimes the market needs a hard number to change its mind. Abbott delivered several.
On Wall Street, analyst sentiment remains constructive. The consensus rating is Buy, with 31 buy ratings and 10 holds. The consensus price target is $121.25, with a median of $120.5. That does not guarantee upside, of course. However, it shows the stock entered earnings with support, even after several target cuts earlier in 2026.
Competitive position also matters. Abbott remains strong in continuous glucose monitoring through FreeStyle Libre, cardiovascular devices, diagnostics, and nutrition brands such as Ensure and Similac. The Libre recall history from earlier in 2026 remains a background issue, but it was not the driver of today's move. The market focused on profit growth, sales growth, and a higher full-year outlook.
Today's rally tells investors that Abbott's earnings base is proving sturdier than the stock price had implied. The recent earnings history also adds context. Before this report, Abbott had beaten estimates in only 3 of the previous 7 quarters. That makes a clean Q2 beat and a guidance increase stand out more than it would for a serial overachiever.
Sentiment has also turned strongly positive. News sentiment over the last 7 days scored 0.9284, with an improving trend across 30 and 90 days as well. That kind of backdrop can amplify an earnings reaction once the numbers give traders a reason to buy.
Actionably, the setup now favors investors who want a large-cap healthcare name with both income and operating momentum. The raised EPS range of $5.45-$5.60 gives the market a firmer profit floor. Meanwhile, the stock remains far from its 52-week high, which leaves room for further recovery if execution stays intact.
That said, discipline still matters. After a 12.48% one-day move, chasing strength without a plan can be expensive. For investors building positions, ABT now looks more compelling as a quality healthcare compounder with renewed earnings momentum than as a deep-value rebound trade.
Abbott Laboratories (ABT) is climbing today because it delivered what the market wanted most: a real earnings beat and a higher profit outlook. With Q2 sales up 13.0%, adjusted EPS at $1.31, and full-year guidance moving higher, the rally has a solid factual base and puts ABT back on the radar as a steadier healthcare growth name.
ABT stock is up because Abbott reported stronger-than-expected Q2 2026 results and raised its full-year adjusted EPS guidance. The market is reacting to the earnings beat, 13% revenue growth, and especially the stronger outlook for profit.
+Should I buy ABT stock now?
The stock looks more attractive after the earnings-driven reset, but the move is already large, so new buyers should be disciplined. The article supports ABT as a quality healthcare compounder, not a chase-the-rally trade.
+What was Abbott Laboratories' latest earnings result?
Abbott reported Q2 2026 adjusted EPS of $1.31 on $12.593 billion in sales. That beat Wall Street expectations and helped trigger the stock’s sharp move higher.
+What changed in Abbott's full-year guidance?
Abbott raised its 2026 adjusted EPS outlook to $5.45-$5.60 from $5.38-$5.58. It also reiterated comparable sales growth guidance of 6.5%-7.5%, which reinforced confidence in the company’s outlook.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on ABT?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
